Mallinckrodt To Present At Leerink Partners Global Healthcare Conference

Jan 28, 2016, 17:00 ET from Mallinckrodt Pharmaceuticals

CHESTERFIELD, United Kingdom, Jan. 28, 2016 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty biopharmaceutical company, will present on Wednesday, Feb. 10, 2016, at the Leerink Partners Global Healthcare Conference at the Waldorf Astoria New York, 301 Park Ave in New York City.

Matt Harbaugh, Senior Vice President and Chief Financial Officer, and Cole Lannum, Senior Vice President of Investor Strategy and Investor Relations Officer, will represent the company in a fireside chat session scheduled at 2:40 p.m. Eastern Time.

Individuals who cannot attend the meeting in person can find webcast information at: A replay will also be available following the meeting.

ABOUT MALLINCKRODT Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


Investor Relations Coleman N. Lannum, CFA Senior Vice President, Investor Strategy and IRO 314-654-6649

Media Rhonda Sciarra Senior Manager, Communications 314-654-8618

Meredith Fischer Senior Vice President, Communications and Public Affairs 314-654-3318

Logo -


SOURCE Mallinckrodt Pharmaceuticals